Instructions for Cyclodinone drops 50 ml
Features
Minimum age from. 18 years
Method of use Oral
Pack quantity 1 pc
Maximum storage temperature allowed, °C 25 °C
Best before date 36M
Storage Conditions In a dry place
Release form Solution
Volume 50ml
Country of manufacture Germany
Active substance Common fruit extract (Vitex agni casti fructuum extract)
Scope Gynecology
Pharmacological group G02CX Other drugs Cyclodinone for use in gynaecology
Registered as Medicinal agent
ATC codes
G02CX03 Agni casti fructus
Clinical-pharmacological groups / Group affiliation
Phytopharmaceuticals used in menstrual disorders, mastodynia and premenstrual syndrome
Active substance
dry extract of common spring fruit
Pharmacotherapy group:
Preparations for the treatment of gynaecological diseases
Storage Conditions
The drug Cyclodinone should be stored in the original packaging in a place not accessible to children at a temperature not higher than 25 ° C.
Best before date
Shelf life is 3 years. Do not apply after expiry date.
Testimony:
Menstrual disorders;
premenstrual syndrome;
mastodinia.
Method of use, course and dosage:
The drug Cyclodinone is taken in 40 drops 1 time/day, in the morning, with a little water.
Duration of treatment - at least 3 months (without interruption during menstruation). After the symptoms disappear and the condition improves, treatment should continue for several weeks after consultation with the doctor.
If symptoms of the disease persist during the use of the drug Cyclodinone, the patient must see a doctor. If after treatment, the complaint reappears, the patient should consult a doctor.
Overdose:
In the case of overdose, the severity of dose-dependent side effects may increase.
Treatment: symptomatic therapy.
Use in liver disorders
With caution: liver disease.
Terms of Sale
The drug is released without a prescription.
Use in children
The use of the drug Cyclodinone in the age of 18 years is contraindicated (there are no data on the effectiveness and safety of the drug in this age group).
Nosology (ICD codes)
E28
Ovarian dysfunction
N64.4
Mastodinia
N94.3
Premenstrual tension syndrome
Pharmacological effect of the drug:
A plant-based remedy. The components of the drug have a normalizing effect on the concentration of sex hormones. Dopaminergic effects of the drug Cyclodinone, causing a decrease in prolactin production, eliminate hyperprolactiinemia. The increased concentration of prolactin disrupts gonadotropins secretion, resulting in follicle maturation, ovulation, and yellow body formation disorders, which further leads to an imbalance between estradiol and progesterone and can cause menstrual cycle disorders as well as mastodynia. Unlike estrogens and other hormones, prolactin also has a direct stimulating effect on proliferative processes in the mammary glands, enhancing connective tissue formation and causing the expansion of the milk ducts. The reduction of prolactin leads to the reverse development of pathological processes in the mammary glands and quashes pain syndrome. Rhythmic production and normalization of gonadotropin hormone ratio leads to normalization of the second phase of the menstrual cycle